Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TLD-1433 by Theralase Technologies for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TLD-1433 is under clinical development by Theralase Technologies and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Data Insights
Risk adjusted net present value: What is the current valuation of Theralase Technologies's TLD-1433?
TLD-1433 is a small molecule commercialized by Theralase Technologies, with a leading Phase II program in Non Muscle Invasive Bladder...